Segment Reporting - Schedule of Total Segment Net Loss to Consolidated Net Loss (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Stock-based compensation expense		$ 1,857	$ 1,691
Interest income		(1,117)	(2,374)
Interest expense		1,406	1,325
Other expense, net		(62)	(51)
Net Loss		28,039	23,347
Operating Segments
Segment Reporting Information [Line Items]
Clinical Expense		6,050	5,751
CMC Expense		6,393	4,226
Other research and development expense	[1]	2,236	3,426
Personnel expense - R&D		5,701	4,362
Personnel expense - G&A		2,231	1,815
Stock-based compensation expense		1,857	1,691
Administrative & facilities expense	[2]	3,221	3,074
Interest income		(1,117)	(2,374)
Interest expense		1,405	1,325
Other expense, net		62	51
Net Loss		$ (28,039)	$ (23,347)

[1] (1) Other research and development expenses primarily consist of consulting, regulatory support, toxicology, sponsored research costs, and other research and development activities.

[2] (2) Administrative & facilities expense primarily consists of facilities expenses, depreciation expense, legal costs, insurance, consulting, and other administrative costs.